Targeting aortic regurgitation with TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences recently acquired the two companies at the center of this study, JenaValve and JC Medical.

One study presented during the three-day conference focused on the potential benefits of an optimized TAVR pathway. Another study, meanwhile, tracked changes in paravalvular leak severity over time.

Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

Daniel West, MD, is suing Trinity Health Muskegon and seeking whistleblower protection after reporting alleged malpractice and being summarily terminated.

The Mediterranean diet, named after the traditional eating habits of Greece and Italy, was once again linked to multiple cardiovascular benefits. The focus of this latest meta-analysis was adults over the age of 60.

Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away.

PPM is still relatively common after TAVR, especially among patients with a small aortic annulus. What can be done to minimize the risk of PPM? Does valve type play a role? Researchers explored those questions, and many others.

Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures.